Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

CSL reports robust earnings growth, led by immunoglobulin sales

EditorEmilio Ghigini
Published 02/13/2024, 05:11 AM
Updated 02/13/2024, 05:11 AM
© Reuters.

MELBOURNE, Australia - CSL Limited (ASX:CSL; USOTC:CSLLY (OTC:CSLLY)), a global biotech leader, announced a significant increase in its financial performance for the six months ending December 31, 2023. The company's net profit after tax (NPAT) rose to $1.90B, marking a 20% increase on a constant currency basis. Underlying profit, or NPATA, also saw a rise to $2.02B, up 13% at constant currency, reaching $2.06B.

The strong financial results were primarily driven by the exceptional performance of CSL Behring, particularly in the immunoglobulin (Ig) sector. Immunoglobulin product sales soared by 23%, with PRIVIGEN®/INTRAGAM® and HIZENTRA® leading the charge, reflecting robust global demand and improved product availability.

CSL Seqirus, the company's influenza vaccine division, managed a solid growth despite a challenging season. Its differentiated product portfolio, including the adjuvanted influenza vaccine FLUAD®, outperformed the market with a 14% increase in sales.

CSL's recent acquisition, Vifor Pharma, contributed to the company's revenue with $1,011M. While the company has moderated its near-term growth expectations for CSL Vifor, preparations are underway for the evolving iron market, and products like MIRCERA® and TAVNEOS® have been successfully launched in multiple European countries.

Research and development expenses were reported at $669M, an 11% increase, reflecting the progression of the company's R&D portfolio. Meanwhile, selling and marketing expenses saw a modest 2% rise, and general and administrative expenses decreased by 7%, attributed to efficiencies from centralizing the group's enabling functions.

CSL's financial position remains robust with a strong balance sheet and a 9% increase in cash flow from operations, driven by higher profitability and sales growth. The company's outlook for the fiscal year 2024 remains positive, with NPATA expected to be in the range of $2.9B to $3.0B at constant currency, indicating a growth of approximately 13-17%.

CEO Dr. Paul McKenzie expressed confidence in CSL's ability to deliver double-digit earnings growth over the medium term, citing strong demand for immunoglobulins and successful initiatives in plasma collections that are enhancing efficiencies.

This report is based on a press release statement by CSL Limited.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.